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A B S T R A C T
Objectives: To evaluate the cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine
(PCV7-TT) into the Cuban National Immunization Program (NIP).
Methods: We compared PCV7-TT given at two, four and six months of age to a scenario without PCV7-TT,
over a ten-year period (2020–2029). We calculated the cost (Cuban pesos – CUP) per Disability Adjusted
Life Year (DALY) averted from a Government perspective. We compared results from a static cohort model
and a parsimonious prediction model informed by the serotype distribution among pneumococcal
carriers and cases. We ran probabilistic and deterministic uncertainty analyses.
Results: PCV7-TT could prevent 6897 (95% uncertainty interval, 4344–8750) hospitalizations and 189
(115–253) deaths in children <5 years of age, over the period 2020–2029. This could cost around 25
million (20–31) discounted CUP but would be offset by treatment cost savings of around 23 million (14–
31). A parsimonious model predicted less favourable impact and cost-effectiveness but the cost per DALY
averted was still less than 0.4 times the current GDP per capita.
Conclusions: PCV7-TT is likely to be cost-effective in Cuba. The impact of the vaccine would need to be
carefully monitored following its introduction into the NIP.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
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Streptococcus pneumoniae is an important cause of severe
bacterial infections in young children and the elderly (Valenzuela
et al., 2009). In Cuba, high rates of nasopharyngeal colonization
have been reported in children <5 years of age (Toledo et al., 2017)
and pneumococcus is one of the main causes of meningitis,
pneumonia, sepsis and acute otitis media (Wahl et al., 2018). The
first licensed pneumococcal conjugate vaccine (PCV7)* Corresponding author at: Finlay Vaccine Institute, Ave 21 #19810 e/198 y 200,
Atabey, Playa, P.O. Box 16042, Havana 11600, Cuba.
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creativecommons.org/licenses/by-nc-nd/4.0/).demonstrated substantial reductions in severe pneumococcal
disease in both vaccinated and unvaccinated individuals (de
Oliveira et al., 2016). Other vaccines covering more serotypes have
subsequently been developed (PCV10 and PCV13) and introduced
in several countries worldwide. The World Health Organization
(WHO) recommends that all countries use PCVs in their national
routine immunization programs (World Health Organization,
2012). Evidence from Latin America has demonstrated the
significant impact of PCVs on hospitalizations in children due to
radiograph-confirmed pneumonia, clinical pneumonia, meningi-
tis, and invasive pneumococcal disease (IPD) (de Oliveira et al.,
2016). In Cuba, the high cost of these vaccines has been an
important barrier to introduction. Since 2006, the Cuban National
Health Service (NHS) and state-owned biotechnology industry
have been developing a domestic heptavalent pneumococcalious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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vaccine is the national market based on the principle of “vaccine
for all, all the time”. This vaccine, PCV7-TT, includes a 2.2 mg
capsular polysaccharide of serotypes 1, 5, 14, 18C, 19F and 23F, and
4.4 mg of serotype 6B, conjugated with tetanus toxoid as a carrier
protein and adsorbed in aluminum phosphate as an adjuvant
(Linares-Pérez et al., 2017). The seven serotypes contained in the
new vaccine candidate represent 42.3% of total IPD in Cuba in 2014
(Organización Panamericana de la Salud, 2015) and account for
over 60% of isolated serotypes worldwide (International Vaccine
Access, 2017). The safety and immunogenicity of PCV7-TT has been
demonstrated in clinical trials of Cuban infants (Martinez et al.,
2018) and preschool children (Dotres et al., 2014). In addition,
PCV7-TT has demonstrated non-inferiority to the efficacy of PCV13
in a randomized double-blind clinical trial (Toledo-Romaní et al.,
forthcoming; Cuban Public Registry of Clinical Trials – code
RPCEC00000243).
While PCV7-TT is expected to cost less than the two globally
licensed vaccines (PCV10 and PCV13), an economic evaluation is
still needed to assess whether it represents good value for money
for the Cuban Government. This study aimed to evaluate the
potential impact and cost-effectiveness of introducing PCV7-TT
into the Cuban National Immunization Program (NIP).
Methods
We compared vaccination with PCV7-TT at two, four and six
months of age to no vaccination, over the period 2020–2029. The
primary outcome measure was the number of Cuban pesos (CUP)
per Disability Adjusted Life Year (DALY) averted, from a Govern-
ment perspective. We did not consider a broader societal
perspective, so excluded all costs borne by households andTable 1
Input parameters for estimating the burden of pneumococcal disease in Cuban childre
Parameter Estimate L
Annual case rate per 100,000 children aged <5 years
Pneumococcal acute otitis media 11,664 9
Pneumococcal non severe pneumonia 80 7
Pneumococcal severe pneumonia 149 1
Pneumococcal meningitis 9 4
Pneumococcal NPNM 36 1
Annual mortality rate per 100,000 children aged <5 years
Pneumococcal severe pneumonia 3.83 2
Pneumococcal meningitis 1.58 0
Pneumococcal NPNM 1.40 0
% of healthy time lost living with disease
Pneumococcal acute otitis media 1.3 0
Pneumococcal non severe pneumoniaa 5.1 3
Pneumococcal severe pneumoniaa 13.3 8
Pneumococcal meningitis 13.3 8
Pneumococcal NPNMa 13.3 8
Mean duration of illness (in days)
Pneumococcal acute otitis media 5 3
Pneumococcal non severe pneumonia 7 3
Pneumococcal severe pneumonia 10 7
Pneumococcal meningitis 10 7
Pneumococcal NPNM 10 7
Age distribution of cases and deaths
<1 m 0% –
<2 m 2% –
<3 m 7% –
<6 m 23% –
<1 year 54% –
<2 year 84% –
<3 year 94% –
<4 year 98% –
<5 year 100% –
a The disability weights for moderate and severe lower respiratory infections were use
further assumed NPNM would have the same disability weight as non-severe pneumocaregivers e.g. out-of-pocket expenditures and lost wages.
Consistent with the recommendations of the Cuban Guide to
Health Economic Evaluations, a 3% discount rate was applied to all
future costs and benefits (base year = 2020) (Gálvez-González,
2004). DALYs were calculated by combining years of life lost due to
pneumococcal mortality (YLLs) and years of life lost due to living
with pneumococcal disease (YLDs). YLLs were calculated using the
estimated life expectancy at the age of pneumococcal death. YLDs
were calculated by multiplying the average duration of illness by
the disease disability (or disutility) weight. All costs were
expressed in 2016 Cuban pesos (CUP). The official exchange rate
for the business sector in Cuba of 1.00CUP = 1.00USD was used
(Hidalgo de los Santos et al., 2000).
Modelling approach
An Excel-based static cohort model (UNIVAC version 1.4) was
used to estimate numbers of pneumococcal cases and deaths in
each week of age between birth and age 5.0 years (https://www.
paho.org/provac-toolkit). For a given week (w) of age, the number
of disease events Dw was calculated as:
Dw ¼ P  S  Aw  ð1  VwÞ
where: P  D  Aw is the number of disease events in week w of
age; Vw is the effect of vaccination in week w of age; P is the
number of person-years lived between birth and age 5.0 years in
the birth cohort evaluated; S is the streptococcus pneumoniae
(pneumococcal) disease event rate per 100,000 per year among
children younger than 5 years before the introduction of
vaccination; and Aw is the proportion of pneumococcal disease
events in children younger than 5 years in week w of age.n aged <5 years
ow High Source
756 13,680 Bardach et al.
2 87 Linares-Pérez et al.
12 170 Linares-Pérez et al.
 18 Linares-Pérez et al.
6 76 Linares-Pérez et al.
.71 3.99 Linares-Pérez et al.
.68 3.28 Linares-Pérez et al.
.60 2.92 Linares-Pérez et al.
.7 2.4 Salomon J et al.
.2 7.4 Salomon J et al.
.8 19 Salomon J et al.
.8 19 Salomon J et al.
.8 19 Assumption
 7 Marrero et al.
 10 Marrero et al., Assumption
 21 Figueredo et al. and Marrero et al.
 21 Figueredo et al. and Marrero et al.
 21 Figueredo et al. and Marrero et al.









d as a proxy for non-severe and severe pneumococcal pneumonia, respectively. We
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of vaccination in each week of age (Vw) was calculated as:
C3w  E3w þ ðC2w  C3wÞ  E2w þ ðC1w  C2wÞ  E1w
where: C3w E3w is the effect contributed by infants that received
all 3 doses; (C2w C3w)  E2w is the effect contributed by infants
that received only 2 doses; (C1w C2w)  E1w is the effect
contributed by infants that received only 1 dose; C1w, C2w, and
C3w are coverage estimates for the first three doses of vaccination
in week w of age; and E1w, E2w, and E3w are efficacy estimates for
the first three doses of vaccination in week w of age. We assumed
no waning of vaccine protection over time.
Pneumococcal disease burden inputs
For each birth cohort, estimates of person-years lived between
birth and age 5.0 years (PY) were based on United Nations
demographic projections (https://population.un.org/wpp/). We
estimated disease event rates (D) separately for pneumococcal
acute otitis media (AOM), non-severe pneumococcal pneumonia,
severe pneumococcal pneumonia, pneumococcal meningitis and
other non-pneumonia/non-meningitis pneumococcal disease
(NPNM) (Table 1). Non-severe and severe NPNM cases were
combined into one category. Pre-vaccination estimates from
Linares et al. were used to estimate the incidence and mortality
rates for severe pneumonia, meningitis and NPNM caused by
pneumococcus (Linares-Pérez et al., 2019). In the same study 1.8
non-severe pneumonia cases were reported for every 1.0 severe
pneumonia case, so this ratio was used to calculate the incidence of
non-severe pneumococcal pneumonia. These estimates of pneu-
mococcal disease incidence and mortality are consistent with
separate published international estimates for Cuba (Wahl et al.,
2018). We estimated 11,664 pneumococcal AOM cases per 100,000
per year <5 years based on a review of estimates from the LatinTable 2
Input parameters for estimating the health and economic impact of PCV7-TT introduct
Parameter Estimate Low
Vaccination coverage (%)
Dose 1 99.5 98
Dose 2 99.5 98
Dose 3 99.5 98
Vaccine efficacy after 3 doses
Pneumococcal AOM 37 21
Pneumococcal non-severe pneumonia 17 6 
Pneumococcal severe pneumonia 69 24
Pneumococcal meningitis 69 24
Pneumococcal NPNM 69 24
Relative efficacy of partial doses
Ratio of 1-dose VE to 3-dose VE 0.51 – 
Ratio of 2-dose VE to 3-dose VE 0.92 – 
Government cost per clinic visit (CUP)
Pneumococcal AOM 81.80 51.
Pneumococcal non-severe pneumonia 163.99 12
Pneumococcal severe pneumoniaa 137.55 79
Pneumococcal meningitisa 147.70 10
Pneumococcal NPNMa 147.70 10
Government cost per hospital admission (CUP)
Pneumococcal severe pneumonia 1182.74 68
Pneumococcal meningitis 2268.3 151
Pneumococcal NPNM 263.83 20
Vaccination programme cost (CUP)
Vaccine dose price 7.00 5.0
Syringe fixed price per dose 0.05 0.0
Safety box price per dose 0.01 0.0
Wastage (% of doses discarded) 0.10 0.1
Incremental system cost per dose 1.27 1.0
a Follow up post-discharge.American region by Bardach et al. (2011), taking the upper estimate
of all-cause AOM incidence (36,000 per 100,000 per year <5 years)
and multiplying by the 32.4% (95% CI 27.1–38.0%) fraction
estimated to be caused by pneumococcus.
Historical time-series estimates of pneumonia deaths have
declined in the absence of vaccination (Liu et al., 2016). Thus, we
assumed the pneumococcal pneumonia mortality rate would
decrease over the 10-year period 2020–2029 at the same rate as
the expected decline in overall under-five mortality i.e. from 5.7 to
4.5 under-five deaths due to any cause per 1000 live births. For
consistency, we made the same assumption for all severe forms of
pneumococcal disease.
The age distribution of pneumococcal disease cases and deaths
<5 years of age was based on estimates for the Americas region
(Russell et al., 2011). A 3-parameter Burr distribution was fitted to
this age distribution (Clark et al., 2019) to calculate the expected
number of cases and deaths in each week of age <5 years.
United Nations estimates of life expectancy by age and year
were used to calculate YLLs from the age/year of pneumococcal
disease death (https://population.un.org/wpp). Disability weights
were taken from the 2015 global burden of disease (GBD) study
(Salomon et al., 2015). The average duration of illness was
estimated for each disease type using information reported in
two Cuban health care utilization and costing studies (Figueredo
Montes de Oca, 2016) (Table 2).
Pneumococcal economic burden inputs
Cuba has an integrated health system with universal coverage.
We assumed one hospital admission per severe pneumococcal
disease case (meningitis, severe pneumonia, NPNM). The
average cost per hospitalization was estimated to be 1183,
2268 and 264 CUP for severe pneumonia, meningitis and NPNM,
respectively, based on a study by Figueredo et al., conducted ation in Cuba
 High Source
.8 100 López-Ambrón et al.
.8 100 López-Ambrón et al.
.8 100 López-Ambrón et al.
 49 Pavia et al
22 Assumption based on Lucero et al
 87 Lucero et al.
 87 Lucero et al.
 87 Lucero et al.
– Mahon et al.
– Mahon et al.
65 110.99 Marrero et al.
0.00 208.50 Marrero et al.
.99 193.43 Marrero et al.
5.69 189.97 Marrero et al.
5.69 189.97 Marrero et al.
2.77 1953.73 Figueredo et al.
3.81 3163.67 Figueredo et al.
8.8 318.87 Figueredo et al.
0 10.00 Finlay Vaccine Institute
5 0.05 Ministry of Health
1 0.01 Ministry of Health
0 0.10 Ministry of Health
7 1.47 De la Hoz-Restrepo et al.
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study included 45 patients who required hospital admission and
in whom pneumococcus was microbiologically isolated between
January 2010 and December 2015 (Figueredo Montes de Oca,
2016) (Table 2). The number and type of resources used by each
patient was calculated based on a review of medical records,
consultation with key informants and direct observation. All
resources were valued using official prices. Total and average
costs were estimated in Cuban pesos. Mean values and confidence
intervals were calculated using the non-parametric bootstrap
method.
For all pneumococcal diseases we assumed one clinic visit per
case. For severe diseases this was assumed to represent a follow-
up visit following discharge from hospital. The average cost per
clinic visit ranged from 82 to 164 CUP. These costs were based on a
2016 study by Marrero et al., at the Policlinico Docente de Playa, a
unit that forms part of the Sentinel Network of Clinical Research,
Surveillance and Impact Assessment of new preventive vaccines
(VacCuba) (Marrero-Araújo et al., 2020). Flow charts were
developed for each clinical outcome of the disease, based on
care guidelines and the expert opinion of 9 physicians (conve-
nience sample) with experience of diagnosing and treating
childhood diseases in primary health care. The experts estimated
the type of resources and quantities used (average, minimum and
maximum) and official (unpublished Ministry of Health) prices
were assigned to each. A mean, minimum and maximum cost was
estimated and reported in Cuban pesos (Table 2).
Vaccination schedule and coverage
The target group for vaccine introduction was infants in the first
semester of life who would receive the vaccine in a 3-dose
schedule, given at 2, 4 and 6 months of age. We did not evaluate a
catch-up campaign or a schedule with booster doses. Following
advice from the Cuban NIP, we assumed that all vaccines were
administered on time. We used the coverage of the first three doses
of pentavalent vaccine Heberpenta1 (DPT-HB-Hib) in 2016 as a
proxy for PCV vaccination coverage over the ten-year period 2020–
2029 (López Ambrón et al., 2018) (Table 2).
Vaccination program costs
The number of doses to be procured was calculated by
multiplying the mid-year population aged <1 year in the birth
cohort of interest by dose-specific coverage and wastage rates.
Vaccine wastage was estimated using data from the NIP. Total
numbers of procured doses were then multiplied by the cost per
dose (assuming a single-dose presentation of 0.7 ml). A PCV7-TT
price of 7.00 CUP per dose was provided by the state-owned
vaccine manufacturer. Cost of syringes and safety boxes were then
added. There was no specific information on the expected
incremental cost to the health system of introducing PCV7-TT
(expansion of cold chain, transportation, materials, training,
supervision and monitoring), so we assumed 1.27 CUP per dose,
based on a systematic review of incremental non-vaccine costs
associated with PCV introduction, by De la Hoz-Restrepo et al.
(2013).
Vaccine efficacy
PCV7-TT was found to have non-inferior vaccine efficacy to
PCV13 in a double-blind phase II-III clinical trial that included
1135 children (Toledo-Romaní ME et al., forthcoming; Cuban
Public Registry of Clinical Trials - code RPCEC00000243).
Efficacy values for PCV7-TT were therefore based on the
reported efficacy of other pneumococcal conjugate vaccines(PCVs) in the scientific literature (Table 2). All efficacy values
were based on published meta-analyses (random effects) of
per protocol vaccine efficacy. We assumed 3-dose vaccine
efficacy of 37% (95% CI 21–49) against pneumococcal AOM
based on the pooled efficacy against all-serotype pneumococcal
AOM from two heptavalent PCVs studied in Finnish infants
(Pavia et al., 2009). We assumed 3-dose efficacy of 69% (95% CI
24–87) against all severe pneumococcal outcomes (meningitis,
severe pneumonia and NPNM) based on pooled efficacy against
all-serotype invasive pneumococcal disease (IPD) from four PCV
studies – Gambia, Philippines, USA and USA (American Indian)
(Lucero et al., 2009). We assumed 3-dose vaccine efficacy of 17%
(95% CI 6–22) against non-severe pneumococcal pneumonia,
which is one quarter of the efficacy value assumed for severe
pneumococcal pneumonia. This reflects the relative efficacy of
PCVs against all-cause clinical pneumonia (6%, 4 studies)
compared to X-ray defined pneumonia (24%, 5 studies) (Lucero
et al., 2009). Thus, the relative difference in efficacy against
these two outcomes was considered a reasonable proxy for the
relative difference in efficacy against non-severe and severe
pneumococcal pneumonia.
We assumed that one dose would have half the efficacy of three
primary doses, and that the ratio between two and three doses
would be 0.92, based on the dose-specific effectiveness of PCV7
against vaccine-serotype IPD in the USA (Mahon et al., 2006).
Vaccine impact inputs for parsimonious prediction model
The proportion of carriage due to vaccine serotypes (CV) and
non-vaccine serotypes (CN) was estimated to be 0.26 (50/187) and
0.73 (137/187) respectively, based on a carriage study of Cuban
children aged 2–18 months conducted between October and
December 2013 in Cienfuegos municipality (Toledo et al., 2017).
The proportion of pneumococcal disease due to vaccine serotypes
(DV) and non-vaccine serotypes (DN) was estimated to be 0.48 (11/
23) and 0.52 (12/23) respectively, based on national hospital
sentinel surveillance of invasive pneumococcal disease among
children aged <24 months in the year 2014 (Toraño-Peraza et al.,
2017). The impact of the vaccine (percentage reduction is all
pneumococcal disease cases and deaths aged <5 years), based on
the parsimonious prediction model described above, was pre-
dicted to be 28.8%. The uncertainty interval was estimated to be
2.2–54.2% based on the 2.5th and 97.5th percentiles of 1000
resampled impact estimates, after resampling CV and DV from
binomial distributions.
Uncertainty analyses
We ran 1000 probabilistic simulations to generate 95%
uncertainty intervals (2.5th and 97.5th percentiles). For simplicity,
all ranges used a Beta-PERT distribution centered around the mid
estimate and using the low and high estimates as the range. These
simulations were also used to calculate the probability that the
vaccine would be cost-effective at different willingness-to-pay
thresholds.
Pneumococcal vaccination is associated with potentially
important but uncertain indirect effects such as herd immunity
and serotype replacement. We therefore re-ran the probabilistic
analysis assuming overall impact from a parsimonious prediction
model rather than the static cohort model. The parsimonious
prediction model has been validated to real-world PCV7 impact in
13 high-income countries (Flasche et al., 2015). This method,
proposed by Flasche et al., assumes full replacement of vaccine-
type carriage with (less invasive) non-vaccine-type carriage,
following introduction of the vaccine. The overall impact of the
vaccine (% reduction in pneumococcal disease <5 years of age) is
Table 3
Undiscounted numbers of disease cases, clinic visits, hospitalisations and deaths
with and without PCV7-TT in Cuba over the ten-year period 2020–2029.
No vaccination PCV7-TT Averted
Cases <5 years 676,038 446,533 229,505
Pneumococcal Acute Otitis Media 660,502 438,592 221,910
Pneumococcal non-severe pneumonia 4530 3831 699
Pneumococcal severe pneumonia 8444 3153 5290
Pneumococcal meningitis 497 186 312
Pneumococcal NPNM 2065 771 1294
Deaths <5 years 302 113 189
Severe pneumococcal pneumonia 170 63 106
Pneumococcal meningitis 70 26 44
Pneumococcal NPNM 62 23 39
Clinic visits 676,038 446,533 229,505
Pneumococcal Acute Otitis Media 660,502 438,592 221,910
Non-severe pneumococcal pneumonia 4530 3831 699
Severe pneumococcal pneumonia 8444 3153 5290
Pneumococcal meningitis 497 186 312
Pneumococcal NPNM 2065 771 1294
Hospital admissions 11,006 4110 6896
Severe pneumococcal pneumonia 8444 3153 5290
Pneumococcal meningitis 497 186 312
Pneumococcal NPNM 2065 771 1294
Figure 1. Probability that PCV7-TT will be cost-effective at different willingness-to-
pay thresholds in Cuba.
The thick black line represents the results based on the static cohort model. The thin
blue line represents the results based on a pseudo-dynamic algorithm adjusted for
local serotype distribution among carriers and cases. The dashed vertical line
represents 0.5 times the current GDP per capita in Cuba.
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1  ½ðCV=CN þ 1Þ=ðDV=DN þ 1Þ
where: CV is the proportion of carriage due to vaccine serotypes, CN
is the proportion of carriage due to non-vaccine serotypes, DV is the
proportion of pneumococcal disease cases due to vaccine serotypes
and DN is the proportion of pneumococcal disease cases due to
non-vaccine serotypes.
Uncertainty intervals (2.5th and 97.5th percentiles) were
calculated by bootstrapping from binomial distributions.
Results
Vaccine effects
Over the ten-year period 2020–2029, we estimate around
11,000 pneumococcal hospitalizations and 300 deaths aged <5
years in Cuba, without vaccination (Table 3). We estimate that
vaccination could lead to a 63% reduction in hospitalizations and
deaths, preventing 6896 (4344–8750) hospitalizations and 189
(115–253) deaths. In addition, we estimate that the vaccine could
prevent around 34% of all pneumococcal disease cases and clinic
visits, with the majority of prevented disease cases being acute
otitis media (around 220,000 disease cases averted).
Costs and cost-effectiveness
Introducing PCV7-TT is estimated to cost around 25 million
discounted CUP over the ten-year period 2020–2029 (Table 4).
Without vaccination, we estimate the cost of disease treatment to
be 58,628,969 discounted CUP (48,572,128 for clinic visits and
10,056,841 for hospitalizations). Equivalent estimates with vacci-
nation are 35,784,420 (32,016,246 for clinic visits and 3,768,175 forTable 4
Discounted cost-effectiveness of PCV7-TT introduction in Cuba over the ten-year perio
No vaccine 
Cost (CUP) of vaccination – 
Cost (CUP) of disease treatment 58,628,969 
DALYs 7990 
Cost (CUP) per DALY averted – hospitalizations). Thus, a large proportion of the costs of
vaccination are estimated to be offset by averted treatment costs
(around 23 million discounted CUP). Most of these averted
treatment costs are associated with avoided clinic visits (around
17 million discounted CUP), of which pneumococcal AOM
represents the largest share. The cost per DALYaverted is estimated
to be 374 CUP per DALY averted (cost-saving – 3465) from a
Government perspective.
Uncertainty analysis
Figure 1 shows the probability that PCV7-TT will be cost-
effective at different willingness to-pay (WTP) thresholds. Based
on a GDP per capita of CUP/USD 8822 for Cuba in the year 2018
(https://data.worldbank.org), there is a 100% probability that the
vaccine would be cost-effective at a willingness-to-pay threshold
set at 0.5 times the current GDP per capita. We also ran several
what-if scenarios. Our results were less favorable to the vaccine
(3300 versus 374 per DALY averted) when we assumed impact
based on the parsimonious prediction model (29% reduction in all
pneumococcal disease outcomes, versus 34–63% for the static
cohort model), but the cost-effectiveness ratio was still less than
0.5 times the current GDP per capita. The dose price at which
PCV7-TT would be cost-saving was estimated to be around 6.25
CUP per dose using the static cohort model, and 4.25 CUP per dose
using the parsimonious prediction model. We estimated less
favourable cost-effectiveness (2248 vs 374) when assuming the
low estimate for all rates of cases, visits, admissions and deaths,
and when assuming the low estimates for all clinic visit and
hospitalization costs (2116 vs 374). Finally, we estimated lessd 2020–2029.
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was removed completely from the analysis.
Discussion
We estimate that introduction of PCV7-TT could prevent a
substantial number of pneumococcal disease cases, clinic visits,
hospitalizations and deaths among Cuban infants over the period
2020–2029. We also estimate substantial treatment cost savings,
with a large share of these costs saved due to averted cases of acute
otitis media. The cost of introducing the vaccine would be around
2.8 million CUP each year, but it is likely that a substantial
proportion of these costs will be offset by disease treatment cost
savings.
Our best estimate of the potential cost-effectiveness of the
vaccine is 374 CUP per DALY averted, from a Government
perspective. This is around 0.05 times the current GDP per capita
in Cuba. Cuba does not have an established willingness-to-pay
threshold for health interventions, but Ochalek et al. have
suggested a threshold for middle-income countries in the region
of 0.4 times GDP per capita, with wide variation between countries
(range 0.1–1.0) (Ochalek et al., 2015). Our analysis indicates that
PCV7-TT is likely to be cost-effective across most values in this
range. When using estimates of vaccine impact based on a
parsimonious prediction model (accounting for local serotype
distributions and potential serotype replacement) our results were
less favorable to the vaccine, but the cost-effectiveness ratio was
still less than 0.4 times GDP per capita. Had we included herd
immunity benefits to unvaccinated individuals in older age groups
(e.g. the elderly) (Kieninger et al., 2015), and averted disabilities
among meningitis survivors, then our results would have been
even more favorable to the vaccine.
A strength of our study is that we were able to use national data
for several input parameters, including the serotype distribution of
carriers and disease cases, the non-inferiority of PCV7-TT to PCV-
13, the expected price of PCV7-TT, and the costs of treating
pneumococcal disease. The decision-support model used in this
analysis allowed a national multidisciplinary team to easily review
and build consensus on all input parameters and scenarios. This
strengthened the national ownership of the analysis and increases
the likelihood that our results will inform national decision-
making.
An important limitation of our analysis is that the model did not
explicitly simulate the transmission dynamics of pneumococcal
infections in Cuba. In the absence of good-quality local evidence on
the age-specific patterns of social mixing and transmission, we
compared our estimates of impact to a parsimonious prediction
model (Flasche et al., 2015) informed by local evidence on the
serotype distribution among carriers and cases. This predicted a
lower impact on pneumococcal disease than our model (29%
versus 34–63%). However, the serotype distributions for pneumo-
coccal carriers and cases were not taken from the same
geographical location within Cuba. There were also relatively
few pneumococcal disease cases (n = 23) after matching the age
range and period of the disease surveillance data to the age range
and period of the carriage study. As a result, there was a good deal
of uncertainty about the predicted impact using this approach (95%
CI: 2–54%). It is somewhat reassuring that our base case (best)
estimates based on the static cohort model were similar to a
separate analysis by Chen et al. In this study the authors estimated
potential impact of 50% (95% CI: 42–57%) for the Latin America and
Caribbean region, using the same parsimonious prediction model,
although it should be noted that this analysis was done for PCV13
rather than PCV7-TT (Chen et al., 2019). The uncertainty associated
with both approaches (static cohort model and parsimonious
prediction model) emphasizes the need for accurate post-introduction surveillance to establish the real-world impact of
the vaccine. This would allow cost-effectiveness to be revisited as
new data emerges.
We did not include a direct comparison between PCV7-TT and
other PCV products such as PCV10 or PCV13. However, PAHO
Revolving Fund prices for PCV10 and PCV13 are not available for
Cuba so PCV7-TT will be competitively priced for the domestic
market. PCV7-TT has also been found to be non-inferior to PCV13 in
studies of Cuban children (Toledo-Romaní et al., forthcoming;
Cuban Public Registry of Clinical Trials – code RPCEC00000243).
However, given the well documented serotype replacement
observed with previous lower-valency pneumococcal conjugate
vaccines, the real-world impact of PCV7-TT will need to be closely
monitored following introduction in order to detect any increase in
pneumococcal disease caused by types not included in the vaccine.
As more post-vaccination evidence emerges, more sophisticated
transmission dynamic models may offer insights into the expected
longer-term impact of the vaccine.
Despite several uncertainties around some of the param-
eters used, our probabilistic uncertainty analysis indicates that
PCV7-TT is likely to be cost-effective in Cuba. Scenarios with
assumptions that were unfavourable to the vaccine did not
dramatically alter the cost-effectiveness ratio (all were less
than 0.4 times GDP per capita) and in all scenarios we
excluded DALYs and costs associated with long-term sequelae
among pneumococcal meningitis survivors. AOM was influen-
tial in our analysis because of high associated health care costs
averted (23 million averted with AOM included, versus 7
million averted without AOM). Because vaccine program costs
(25 million) were so finely balanced with health care costs
averted (23 million), excluding AOM was particularly influen-
tial on the cost per DALY (374 with versus 3546 without). This
is an interesting result. Although most published studies have
included AOM (Wu et al., 2015; Saokaew et al., 2016), it has
not been particularly influential on the results. Our estimates
of the incidence of AOM, treatment costs and efficacy, were
uncertain, and better evidence is needed to validate these
assumptions. It is reassuring therefore that the results remain
cost-effective (below the GDP per capita of CUP/USD 8822)
when AOM is excluded from the analysis.
In general, better parameters should be sought to validate our
inputs. For example, the costs of disease treatment were based on
just one hospital and one polyclinic. However, in the Cuban health
system, clinical management guidelines are standardized across
the country for pneumonia and meningitis so these estimates
should be a good indication of the costs in other Cuban health
facilities.
We used a government perspective and incorporated only
direct costs. The government perspective was selected because
100% of the Cuban population receives health care services from
governmental institutions. The study allowed us to estimate the
direct medical costs that would be saved by the government if the
vaccine were introduced nationwide. We excluded out-of-pocket
expenses and lost productivity incurred by households because
they would be difficult to estimate at the national level and
including them would only make the case for vaccination more
favourable.
Cuba operates in an economic environment characterized by a
considerable degree of dualism and segmented markets. Three
currencies are currently in circulation: the Cuban peso (CUP), the
US dollar (USD) and the Cuban convertible peso (CUC). There is no
exchange market for CUC into dollars, but in commercial and
financial transactions companies operate with a one-to-one
exchange rate, and do not have bank accounts or separate
accounting for these two types of currency. Companies prepare
their balance sheets using the official exchange rate (one CUP to
188 A. García Fariñas et al. / International Journal of Infectious Diseases 97 (2020) 182–189one USD or CUC). There is an overvaluation of the CUP that affects
the entire economy. On this basis, cost-effectiveness comparisons
with other countries should be made with caution, but the results
when compared with the threshold defined by the country's GDP
are not affected because GDP is also affected by this structural issue
of the current Cuban economy.
In conclusion, PCV7-TT is likely to be cost-effective in Cuba. The
real-world impact of PCV7-TT would need to be closely monitored
following introduction in order to detect any increase in
pneumococcal disease caused by types not included in the vaccine.
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